



## **ME THERAPEUTICS HOLDINGS INC. ANNOUNCES GRANT OF STOCK OPTIONS**

VANCOUVER, BC – April 8, 2024 – ME Therapeutics Holdings Inc. (METX:CSE) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, announces that it has granted (the “Grant”) 250,000 incentive stock options (each, an “Option”) to purchase up to 250,000 common shares of the Company (each, a “Share”) to an arm’s length consultant of the Company under its Stock Option Plan. The Options are exercisable for a period of three years from the date of Grant, expiring on April 8, 2027, at a price of \$3.51 per Share, and vest as follows: (i) 25% on the date of the Grant, (ii) 50% on the date that is six months after the date of Grant; and (iii) 25% on the date that is nine months after the date of Grant.

All Options and the Shares underlying such Options are subject to a hold period of four months and one day from the date of issuance.

### **ME Therapeutics Holdings Inc.**

Myeloid Enhancement (ME) Therapeutics is an early stage Vancouver based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-cancer immunity. For more information, please visit [www.metherapeutics.com](http://www.metherapeutics.com) and the Company’s profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca)

### **ON BEHALF OF THE BOARD**

“Salim Dhanji”

Dr. Salim Dhanji, PhD  
Chief Executive Officer and Director

For further information, please contact:

Dr. Salim Dhanji  
Telephone: (236) 516-7714

*The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.*